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1. Introduction  
Tumors of the central nervous system (CNS) encompass a wide variety of entities, which span 
from benign to highly malignant. The classification of these tumors is typically based on their 
histopathological features or their location within the CNS. Despite these apparently simple 
criteria, there are a great number of independent CNS tumor types as defined by the most 
recent World Health Organization (WHO) classification of CNS tumors (Louis et al., 2007), 
which is the standard for the definition of CNS tumors worldwide. The WHO listing of CNS 
tumors is impressively vast and has, in fact, been surrounded by some controversy concerning 
the nosology of some tumor entities (e.g., the nosologic place of highly anaplastic 
oligoastrocytic tumors, glioblastoma with oligodendroglioma components). The age-
standardized incidence rate of all primary non-malignant and malignant CNS tumors in the 
US is 16.5 per 100,000 person–years (9.2 per 100,000 person–years for non–malignant tumors 
and 7.3 per 100,000 person–years for malignant tumors) (CBTRUS, 2010). This rate is higher in 
females (17.2 per 100,000 person–years) than males (15.8 per 100,000 person–years). 
Worldwide data is available only for malignant primary CNS tumors; in this setting, the 
incidence rates are higher in males (approximately 3.7 per 100,000 person-years) than females 
(2.6 per 100,000 person–years) (Ferlay et al., 2008). In Western Europe, the male and female 
incidence rates of malignant CNS tumors are 6.7 per 100,000 person-years and 4.5 per 100,000 
person-years, respectively. Very similar figures are observed in Northern America (6.0 and 4.5 
per 100,000 person-years for males and females, respectively). Interestingly, the incidence rates 
are higher in more developed countries than in less developed ones, but these differences may 
be a consequence of differences in diagnostic practices, completeness of reporting and access to 
adequate health care, rather than attributable to geographic and genetic variation. 
CNS tumors are considered to be primary when the tumor originally initiates in the CNS, as 
opposed to the far more common brain metastases derived from malignant tumors located 
in other organs, which are considered secondary brain tumors. Primary brain and CNS 
tumors account for only approximately 2% of all primary tumors (Louis et al., 2007), but 
they rank first among tumor types for the average years of life lost (~20 years, compared, for 
example, with ~6 years for prostate cancer and ~12 years for lung cancer) (Burnet et al., 
2005). These tumors are the most frequent solid malignancy in children, being the leading 
cause of cancer-related death in children under the age of 19 (Rickert & Paulus, 2001). The 
impact and nature of primary brain tumors in adults is somewhat different, but they still 
rank second as cause of cancer death in males aged 20 to 39 years, and fifth in females of 
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those same ages (Jemal et al., 2009). This chapter will not fully review all the types of brain 
and CNS malignancies, but rather focus more specifically and thoroughly in gliomas, the 
most common type of all primary brain tumors. 
2. Classification and epidemiology of gliomas 
Glioma is a broad category of tumors divided into histological subgroups based on the type 
of glial cell of origin or morphological similarities between tumor and normal glial cells: 
astrocytomas (derived from astrocytes or their precursors), oligodendrogliomas (derived 
from oligodendrocytes or their precursors), and  oligoastrocytomas (mixed lineage) are the 
three major subgroups, while ependymomas (derived from ependyma or their precursors) 
are less common  (Louis et al., 2007). They represent 36% of all primary brain and CNS 
tumors, and account for approximately 81% of those that are malignant, an occurrence most 
likely related to the fact that the number of glial cells in the CNS is an order of magnitude 
higher than that of neurons. In addition, glial cells retain the ability to proliferative 
throughout adulthood, while most neurons do not, a characteristic that may also contribute 
to the higher incidence of this tumor group.  
The WHO classification of CNS tumors is the most commonly used classification system 
among the medical and research community. This system classifies gliomas according to the 
presumed cell of origin based on similarities of tumor cells and non-neoplastic glial cells, as 
determined by histological analysis. Additionally, gliomas can be graded I to IV based on 
their degree of differentiation and malignancy (Louis et al., 2007), which can help predict the 
likely behavior of the tumor. Glioma grading is typically based on tumor cells’ 
characteristics like mitotic index, nuclear atypia, vascular proliferation and necrosis (Louis 
et al., 2007). Simply put, grade I tumors often present well differentiated cells, are 
biologically benign and can be cured; grade II gliomas are malignancies that may follow 
long clinical courses, but early diffuse infiltration of the surrounding brain renders them 
incurable by surgery; grade III tumors exhibit increased anaplasia and proliferation, being 
more rapidly fatal; grade IV tumors exhibit more advanced features of malignancy, such as  
vascular proliferation and necrosis, and are generally lethal within 12 months. In general, 
grades I and II tumors are considered low-grade, while grades III and IV are high-grade 
tumors. The cell of origin of gliomas is a matter surrounded by controversy: for a long time, 
gliomas were believed to arise from differentiated glial cells, but this paradigm has recently 
been called into question, as some evidences suggest that these tumors arise from stem cells 
or lineage-committed progenitor cells (Singh et al., 2004). For the purposes of this chapter, 
the three major histological types of glioma (astrocytomas, oligodendrogliomas, and 
oligoastrocytomas) are discussed with particular emphasis. 
2.1 Astrocytomas 
Astrocytic tumors, or astrocytomas, are the most common intracranial neoplasms, 
accounting for approximately 75% of all gliomas (CBTRUS, 2010). Despite sharing a same 
cell of origin, astrocytoma is a broad category of tumors with different characteristics that 
differ in their location within the CNS, age and gender distribution, morphological features, 
growth potential, extent of invasiveness, tendency for progression, and clinical course. 
These are distinctly classified into four major clinicopathological entities, mostly based on 
their degree of malignancy: pilocytic astrocytomas (WHO grade I), diffuse astrocytoma 
(WHO grade II), anaplastic astrocytoma (WHO grade III) and glioblastoma multiforme 
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(GBM, WHO grade IV). A brief summary of the main characteristics of these tumor types is 
given below, with a special emphasizes on the most common and malignant type, GBM. 
Pilocytic astrocytomas (WHO grade I) account for ~5.8% of all gliomas, with similar 
frequencies in both males and females. Sometimes these are also referred to as “juvenile 
pilocytic astrocytoma”, as they occur predominantly in children and teens, being the most 
common CNS tumor type among people under the age of 19 (CBTRUS, 2010). Diffuse 
astrocytomas (WHO grade II), sometimes called low-grade astrocytomas, account for ~1.5% 
of all gliomas and occur most commonly in young adults between the ages of 20 to 40. A 
slight male predominance (male-to-female ratio of 1.18:1) has been reported (Louis et al., 
2007). This diffusely infiltrative nature may in part contribute to the typical progression of 
these tumors to more malignant neoplasms like anaplastic astrocytoma and, ultimately, 
glioblastoma. Three histologic entities can be distinguished: fibrillary astrocytoma (the most 
common), gemistocytic astrocytoma, and protoplasmic astrocytoma (Louis et al., 2007). 
Anaplastic astrocytomas (WHO grade III) are high-grade gliomas which may arise from a 
low grade diffuse astrocytoma or may arise de novo, i.e., without clinical evidence of a less 
malignant precursor lesion. These tumors account for approximately 7.5% of all gliomas, 
affect males more frequently than females (reported male to female ratios range from 1.1:1 
to 1.6:1) and show a peak of incidence in adults aged between 30 to 50 years (Louis et al., 
2007). In most cases, these grade III malignancies will progress to glioblastoma, showing a 
mean time to progression of ~2 years (Louis et al., 2007).  Glioblastoma (WHO grade IV), or 
glioblastoma multiforme (GBM), is the most frequent and most malignant brain tumor, 
accounting for approximately 51% of all primary gliomas (CBTRUS, 2010). In Europe and 
North America, the incidence rates are approximately 3 new cases per 100,000 people per 
year. The peak of incidence occurs in adults aged 45 to 70 years, but glioblastoma can 
develop at any age.  Males are more frequently affected (male to female ratio 1.7:1), and the 
frequency of glioblastoma in Caucasians is two times higher than in blacks. From a clinical 
and biological perspective, two main subtypes of this malignancy can be distinguished: 
primary (or de novo) glioblastoma develop without the presence of any precursor neoplastic 
lesion and manifest after a short clinical history (usually less than 3 months); secondary 
glioblastoma develop from lower grade tumors (a diffuse astrocytoma or an anaplastic 
astrocytoma) (Ohgaki & Kleihues, 2007). Primary glioblastoma, which are by far the most 
common, affect primarily older patients, present a quicker tumor progression and a poorer 
prognosis, as compared to secondary GBM. Of note, primary and secondary glioblastomas 
are histologically indistinguishable, but a growing body of data has been suggesting that 
these two disease entities evolve through different molecular mechanisms (as further 
detailed later in this chapter). Two histological variants of glioblastoma include: i) giant cell 
glioblastoma (WHO grade IV) is a rare variant (less than 5% of glioblastomas) composed of 
atypic multinucleated giant tumor cells; ii) gliosarcoma (WHO grade IV) accounts for 
approximately 2-8% of all glioblastomas (Homma et al., 2006; Meis et al., 1991), and is 
characterized by a biphasic tissue pattern with alternating areas displaying glial and 
mesenchymal differentiation.  
2.2 Oligodendrogliomas 
Oligodendroglial tumors account for approximately 8.4% of all gliomas, affecting males 
slightly more frequent than females (male to female ratio 1.1:1) (CBTRUS, 2010). The age 
distribution of oligodendrogliomas shows a peak of incidence in adults aged 40 to 50 years, 
but they may also rarely affect children (only 2% of all brain tumors in patients younger 
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than 14 years). Based on their degree of malignancy and other histopathological features, 
two histological subtypes are distinguished: oligodendroglioma (WHO grade II) and 
anaplastic oligodendroglioma (WHO grade III). These two entities encompass a continuum 
of neoplasms which range from well-differentiated to highly malignant (Louis et al., 2007). 
Oligodendroglioma (WHO grade II) account for approximately 6% of all gliomas 
(CBTRUS, 2010). Anaplastic oligodendroglioma (WHO grade III) accounts for 
approximately 2.4% of all gliomas (CBTRUS, 2010). Similarly to high-grade astrocytomas, 
anaplastic oligodendroglioma may develop de novo or by progression from a pre-existing 
low grade oligodendroglioma (WHO grade II). 
2.3 Oligoastrocytomas (mixed gliomas) 
Oligoastrocytomas are diffusely infiltrating gliomas that present with a mixture of two 
morphologically distinct tumor cell types, resembling the neoplastic cells present in 
astrocytomas and oligodendrogliomas (Louis et al., 2007). As such, these tumors are also 
often called “mixed glioma”. Precise and consistent epidemiological data on 
oligoastrocytoma are not yet available, but they have been reported to account for 
approximately 2-9% of all gliomas, affecting preferentially males (male to female ratio 1.3:1). 
Median ages range from 35 to 45 years (CBTRUS, 2010). Oligoastrocytomas, like 
astrocytomas and oligodendrogliomas, are divided into low grade (WHO grade II) and 
high-grade (WHO grade III) oligoastrocytoma, based on the most aggressive type of 
neoplastic cell present in the tumor. 
3. Etiology and risk factors for glioma 
Typical risk factors for a variety of human tumors, including genetic and environmental 
factors (such as tobacco smoking, diet, excessive alcohol intake, occupational exposure to 
carcinogens, exposure to UV radiation, and some other personal habits), have not been 
consistently correlated with risk for glioma (Fisher et al., 2007). Epidemiological data 
suggest that approximately one third of all human cancers are related to dietary factors and 
lack of proper physical activity in adulthood. Additionally, a significant number of these 
could be prevented by vaccination (e.g., viral-related tumors) and/or behavioral changes 
(e.g., tobacco-related tumors and skin cancer), as their risk factors are well known. In 
contrast, reliable recommendations to prevent gliomas cannot be endorsed presently, as the 
etiology of glioma remains largely obscure. A brief summary of the most relevant potential 
risk factors for glioma are briefly reviewed below. 
3.1 Environmental risk factors 
Exposure to high-dose therapeutic radiation is the only firmly established exogenous 
environmental cause of glioma, which can clinically manifest only several years after the 
exposure (Ohgaki & Kleihues, 2005). Recent data suggest that use of high-dose 
chemotherapy to treat other tumors may also contribute to gliomagenesis (Edick et al., 
2005). Interestingly, the degree of risk from these exposures to radiotherapy and 
chemotherapy may be influenced by the individual’s genetic background; for example, a 
functional germline polymorphism in the thiopurine methyltransferase gene was shown to 
affect the susceptibility of children treated with cranial radiotherapy and intensive 
antimetabolite therapy for acute lymphocytic leukemia to further develop brain tumors 
(Relling et al., 1999).  However, similar studies are needed to confirm these observations and 
extend its conclusions to adults. 
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Throughout life, people are exposed to a variety of endogenous and exogenous chemicals 
(for example, reactive oxygen and nitrogen species, N-nitroso compounds, several 
industrially used chemicals, and polycyclic aromatic hydrocarbons) through cellular 
metabolism, diet, occupation, and personal habits. Some of these compounds have been 
shown to be biologically plausible neurocarcinogens in a great number of animal and other 
studies; however, inconsistent or null findings have been reported for these same factors in 
human studies (reviewed in Wrensch et al., 2005). These inconsistent data among several 
association studies may result from a variety of issues, including small study sample sizes, 
false-positive results (due to both small sample size and lack of accurate statistical 
hypothesis), imprecise exposure measures (from proxy reporting and exposure history recall 
issues), protective exposures or conditions unaccounted for (e.g., allergies), variation in 
metabolic and repair pathways in the brain, differential diffusion of chemicals across the 
blood–brain barrier, and disease heterogeneity. 
A currently hot topic is the potential association between cellular phone usage and glioma 
risk. While one study reported increased risk for glioma associated with long term (≥10 
years) use of cellular phones (Hardell et al., 2007), other larger studies have failed to 
replicate this (Lahkola et al., 2007; Inskip et al., 2001; Fisher et al., 2007). 
It is plausible that the failure to find strong and consistent associations between 
environmental risk factors and gliomas might be simply a reflection of absence of true 
associations (and not due to research issues). Nevertheless, considering the small number of 
studies examining environmental risk factors for specific well-defined glioma subtypes, it is 
premature to irrefutably conclude that environmental risks do not exist for glioma. 
3.2 Genetic syndromes, familial aggregation, and mutagen sensitivity 
Studies of genetic syndromes, familial aggregation, linkage, and mutagen sensitivity have 
suggested that genetics has an effect on susceptibility to glioma. Particular inherited rare 
genetic mutations cause a small number of genetic syndromes that have been associated 
with increased risk of glial tumors. Although these familial tumor syndromes account for a 
small proportion of cases (Ichimura et al., 2004), the elucidation of their molecular basis has 
greatly contributed to the understanding of gliomas, and has provided a valuable starting 
point for identifying candidate genes and pathways involved in gliomagenesis. 
In large, carefully-designed epidemiological studies, familial glioma risks have been 
reported to be approximately two-fold, a magnitude that is similar to the familial association 
reported for other cancers for which susceptibility genes have been identified (e.g., breast 
cancer) (Malmer et al., 1999; Hemminki et al., 2000; Wrensch et al., 1997). The underlying 
causes of the pattern of familial brain tumor occurrence have been attributed to a variety of 
causes: one study implicates environmental factors only (Grossman et al., 1999), while 
others attribute multifactorial causes, polygenic causes, and autosomal recessive inheritance 
(de Andrade et al., 2001; Malmer et al., 2001). 
Two case-control studies have suggested that peripheral lymphocytes from glioma patients 
are more sensitive to gamma-radiation than lymphocytes from matched controls, suggesting 
that increased sensitivity to radiation is an independent risk factor for gliomas (Bondy et al., 
1996; 2001). The authors also propose that inherited genetic variation in the capacity to 
repair radiation damage may partly influence mutagen sensitivity and, ultimately, glioma 
risk. 
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3.3 Genetic polymorphisms 
Since high-dose therapeutic radiation and inherited rare mutations explain only a small 
proportion of gliomas, neuro-oncology research has focused on genetic polymorphisms that, 
together with environmental risk factors, might potentially affect susceptibility to gliomas. 
Some of the most frequently studied polymorphisms, in the context of glioma, are in genes 
involved in DNA repair, carcinogen metabolism, cell cycle regulation, and immunological 
responses.  
Because DNA repair is a mechanism of utmost importance in preserving genomic integrity, 
genes involved in this pathway have been extensively studied in human tumors. Glioma 
and some histological subtypes have been associated with specific polymorphic variants of 
particular DNA repair genes, such as ERCC1 (excision repair cross-complementing 1), 
ERCC2 (excision repair cross-complementing 2), GLTSCR1 (glioma tumor suppressor 
candidate region gene 1), PRKDC (protein kinase, DNA-activated, catalytic), and MGMT 
(O6-methylguanine-DNA methyltransferase) (Wang et al., 2004; Wiencke et al., 2005; 
Wrensch et al., 2005; Yang et al., 2005). However, the clear reliability of these findings is still 
requiring further studies to assess consistency. The DNA repair pathway is extraordinarily 
complex, as illustrated by the more than 130 genes known to be involved in base excision 
repair, direct reversal of damage, mismatch repair, nucleotide excision repair, homologous 
recombination, nonhomologous end joining, sanitization of nucleotide pools, activity of 
DNA polymerases, editing and processing of nucleases, and postreplicative repair (Wood et 
al., 2001). Studying genetic variants in this panoply of DNA repair genes might contribute to 
a better understanding of gliomagenesis, progression, and response to therapy (mostly DNA 
targeting agents). 
Some of the most intriguing and consistent findings of the past decade of neuro-oncology 
research are the statistically significant inverse associations between risk of gliomas in 
adults and histories of allergies and/or chickenpox, IgG antibodies to varicella-zoster virus, 
and levels of serum IgE (Wiemels et al., 2004; Wrensch et al., 2001; 2005). A later study used 
germline polymorphisms in genes associated with asthma and allergies (IL-4RA, IL-13 and 
ADAM33) as biomarkers for the presence of these conditions, as genetic polymorphisms 
could not be influenced by the presence of glioma. Remarkably, specific genotypic variants, 
which have been shown to increase asthma risk, were equally associated with decreased risk 
for glioblastoma (J. Schwartzbaum et al., 2005), further supporting the findings from self-
reported case-control studies. 
We have recently investigated genetic variants potentially relevant for glioma in the 
EGF/EGFR pathway, one of the most important growth signaling networks in human 
tumors, whose significance in gliomas has been well established. Previous studies have 
reached inconsistent conclusions regarding the relevance of a polymorphism in the EGF 
gene (EGF+61 A/G) as a risk factor for glioblastoma (Bhowmick et al., 2004; Vauleon et al., 
2007). Later, we showed that the G allele increases the risk for gliomas, including 
glioblastoma and oligodendroglioma (Costa et al., 2007). Importantly, we have conclusively 
showed that the G variant of EGF+61 is associated with increased promoter activity, which 
may partly explain its relevance for glioma risk. In the EGFR gene, three polymorphisms 
have been described as having a transcriptional regulatory function: two single nucleotide 
polymorphisms in the essential promoter region, -216G/T and -191C/A, and a polymorphic 
(CA)n microsatellite sequence in intron 1. Preliminary studies by our group seem to indicate 
that the -191CA genotype is associated with higher risk for glioma, particularly 
oligodendroglioma, and that shorter (CA)n repeat variants are significantly associated with 
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increased risk for glioma, particularly glioblastoma and oligodendroglioma (Costa et al., 
2010c). In contrast to a study by Carpentier et al. (2006), our preliminary data does not seem 
to implicate the -216G/T polymorphism as a risk factor for glioblastoma. 
Our understanding of cancer as a multi-factorial disease, in which several pathways 
contribute to various stages of tumorigenesis, warrants the need for more integrative studies 
to evaluate interactions among these pathways. Accordingly, the simultaneous study of 
DNA repair, detoxification metabolism, cell cycle, and immunological pathways will allow 
more proper evaluation of different molecular players in gliomagenesis. 
4. Molecular pathology of glioma 
During the past two decades, remarkable progress has been accomplished in the 
understanding of the molecular pathology of gliomas. Similarly to the multistep process of 
human tumorigenesis in other human tissues (Hanahan & Weinberg, 2000), malignant 
transformation of normal cells (either differentiated glial or stem or progenitor cells) into 
gliomas results from the sequential accumulation of molecular aberrations (Ohgaki & 
Kleihues, 2007; Furnari et al., 2007). Tumor-associated molecular dysregulation can occur at 
the genetic and epigenetic levels, including chromosomal gains or losses, gene mutation, 
amplification, deletion, DNA and histones methylation or demethylation, and 
transcriptional regulation (Ichimura et al., 2004); (Wen & Kesary, 2008). An overview of 
some important molecular pathways in the development of gliomas is summarized in 
Figure 1, and briefly discussed below. 
4.1 Chromosomal aberrations 
Cytogenetic studies of gliomas have identified several chromosomal regions with copy 
number alterations (deletions, amplifications, gains, and losses). Typically, the presence of 
loss of heterozygosity (LOH) and deletions in tumors might point to chromosomal regions 
with tumor suppressor genes (those that normally function to suppress tumor 
formation/progression), while amplifications and chromosomal gains might indicate 
regions with oncogenes (those whose function favors tumorigenesis). However, these 
hints may be more difficult to interpret; strikingly, some particular chromosomal regions 
are commonly gained or lost in glioma. To make things a little more complex, the 
definition of tumor suppressor genes and oncogenes is highly context-dependent (e.g., on 
the tumor’s location and intrinsic characteristics), as some proteins play roles that, 
depending on the tissue and cellular context,  may favor or hamper tumorigenesis (Haber 
& Harlow, 1997). 
Combined loss of chromosome arms 1p and 19q is the most frequently detected aberration 
in oligodendroglial tumors (Jeuken et al., 2004). Grade II and grade III oligodendrogliomas 
are equally affected by these chromosomal lesions, suggesting an early role in 
oligodendroglial tumorigenesis. Since losses of chromosome 1p and 19q are intimately 
correlated (Jenkins et al., 2006), it is plausible that the corresponding putative tumor 
suppressor genes may be involved in biologically distinct pathways, which may act 
synergistically in oligodendroglial tumorigenesis. Allelic losses of chromosomes 9p and 10q, 
and homozygous deletion of CDKN2A on chromosome 9p21, are also frequent in anaplastic 
oligodendroglioma (WHO grade III) (Bigner et al., 1999; Ueki et al., 2002). Chromosomal 
aberrations are also present in the majority (~70%) of both primary and secondary 
glioblastoma, which present LOH of chromosome 10q (Behin et al., 2003).  
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Fig. 1. Major signalling pathways commonly altered in glioblastomas: RTK/RAS/PI3K, p53, 
and RB. Red and blue boxes indicate proteins with activating and inactivating alterations, 
respectively, which can be genetic (gene amplifications or deletions, chromosomal copy 
number alterations and translocations, and mutations) and/or epigenetic (DNA CpG island 
hypermethylation, gene specific and global genome-wide DNA hypomethylation, and 
aberrant histone modifications). The frequency of alterations found in GBM in each pathway 
is indicated in the dashed boxes. 
4.2 Dysregulated pathways 
The histological heterogeneity of gliomas parallels with a substantial degree of molecular 
heterogeneity, both within and between histological subtypes of glioma (Rasheed et al., 
1999; Freije et al., 2004). Several interconnected pathways are commonly altered in glioma, 
typically those governing cell-cycle regulation (cellular proliferation and senescence), 
cellular survival (apoptosis and necrosis), invasion (adhesion and migration), and 
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angiogenesis. These molecular abnormalities result in cell’s self-sufficiency with respect to 
growth signals, insensitivity to growth-inhibitory stimuli, evasion of programmed cell 
death, “limitless” replicative potential, sustained angiogenesis, tissue invasion, and 
metastasis. 
4.2.1 Receptor tyrosine kinase (RTK) pathways 
Gliomas typically present overactivation of many mitogens (growth factors) and their 
specific membrane receptors. In order to proliferate, normal cells require activation of 
mitogenic signaling pathways (upon binding of diffusible growth factors to their specific 
transmembrane receptors) and subsequent intracellular signal transduction, which occurs 
mostly through the PI3K and MAPK signaling pathways. In contrast, acquired molecular 
alterations in tumor cells decrease their dependence on exogenous growth stimuli, 
facilitating their aberrant cell division, survival, and motility. While multiple mechanisms 
contribute to the ability of gliomas to overcome normal impositions on the control of 
mitogenic signaling (MAPK and PI3K/PTEN/AKT pathways, among others), abnormal 
activation of receptor tyrosine kinases (RTKs) seems to be the predominant (and better 
studied) mechanism. 
Activation of receptor tyrosine kinase pathways in gliomas occurs through a variety of 
mechanisms, including overexpression of both ligands and receptors (leading to autocrine 
activating loops), gene amplification, and/or mutation of the receptor (resulting in 
constitutive activation even in the absence of the ligand). In addition, particular genetic 
polymorphisms may influence the expression of some of the genes involved in these 
pathways. The two most important receptor-driven signaling pathways in both CNS 
development and gliomagenesis are the epidermal growth factor (EGF) and platelet-derived 
growth factor (PDGF) pathways. 
It is well established the importance of EGF receptor (EGFR) in development and 
differentiation of normal astrocytes (Burrows et al., 1997), but this RTK also plays critical 
roles in glial tumors (Kapoor & O'Rourke, 2003; Rao, et al., 2003). EGFR gene amplification is 
found in a variety of solid tumors, being notably frequent in astrocytomas (up to ~40% of all 
glioblastomas) (Viana-Pereira et al., 2008; Wong et al., 1992). These amplified versions of 
EGFR often undergo genetic rearrangements (e.g., EGFRvI, EGFRvII),  some of which are 
relevant for the oncogenic and malignant roles of EGFR (Ekstrand et al., 1992). EGFRvIII 
(also known as EGFR, or EGFR*), which shows  an in-frame deletion of exons 2–7, is the 
most common EGFR mutant allele,  occurring up to 30% of all human GBM (and in up to 
60% of those that have amplified wild-type EGFR) (Frederick et al., 2000). EGFRvIII protein, 
which exhibit constitutive ligand-independent tyrosine kinase activity, has been found to 
enhance tumorigenic behavior of human glioblastoma cells by reducing apoptosis and 
increasing proliferation (Nagane et al., 1996) and to malignantly transform murine Ink4a/Arf 
null neural stem cells (NSCs) or astrocytes in the mouse brain (Holland et al., 1998; Bachoo 
et al., 2002) making it an attractive and validated therapeutic target in glioma. 
PDGF receptor- (PDGFR-), along with its specific ligands PDGF-A and PDGF-B, are also 
commonly overexpressed in gliomas, particularly in high-grade tumors (Westermark et al., 
1995). In contrast, strong expression of PDGFR- occurs mostly in proliferating endothelial 
cells in glioblastoma. PDGF-C and PDGF-D are also frequently expressed in glioma cell lines 
and in glioblastoma tissues (Lokker et al., 2002). Autocrine and paracrine signaling loops 
may be the primary means by which the PDGFR axis exerts its effects in gliomas, as these 
tumors often demonstrate coexpression of both PDGF ligands and receptors. The 
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importance of this signaling axis in gliomas has been supported by several recent studies: 
PDGF was shown to stimulate NSCs in the adult subventricular zone that express PDGFR- 
to form glioma-like lesions in the mouse (Jackson et al., 2006); in addition, mice transgenic 
for neural progenitor PDGF-B expression resulted in the formation of oligodendrogliomas 
and forced elevation of PDGF-B levels increased overall tumor incidence (Dai et al., 2001; 
Shih et al., 2004). This growing body of data suggests that targeted therapy against this 
pathway could have therapeutic potential. 
4.2.2 The PI3K-AKT pathway 
Along with alterations in cell cycle regulatory pathways and RTK pathways, intracellular 
signaling pathways are also critical in glioma. Some important examples include the MAPK 
pathway (which plays a wide variety of cellular functions, such as regulation of cell-cell 
interactions, composition of extracellular matrix, and expression of genes promoting cell 
cycle progression (Dhanasekaran & Johnson, 2007), and the PI3K/AKT pathway (involved 
in an extraordinary diverse group of cellular functions, including cell growth, proliferation, 
differentiation, motility, survival and intracellular trafficking). Gliomas typically show 
increased activity of several molecular components of the MAPK and PI3K/AKT pathways, 
while some tumor suppressor genes that negatively regulate these pathways are often 
inactivated (Konopka & Bonni, 2003). For example, inactivating mutations in the tumor 
suppressor gene phosphatase and tensin homolog deleted on chromosome 10 (PTEN), 
whose protein is a negative regulator of the PI3K/AKT pathway, contribute to the abnormal 
activity of the pathway. 
The class IA PI3Ks are heterodimers consisting of one regulatory subunit [one of five 
isoforms encoded by three genes: p85, p55, and p50 (PIK3R1); p85 (PIK3R2); and p55 
(PIK3R3)] and a catalytic isoform [p110 (PIK3CA), p110 (PIK3CB) and p110 (PIK3CD)]. 
Activated RTKs recruit class IA PI3Ks to the membrane through their regulatory subunit. 
Activation of class IA PI3Ks at the membrane results in phosphorylation and conversion of 
the lipid phosphatidylinositol-(4,5)-bisphosphate (PIP2) into phosphatidylinositol-(3,4,5)-
triphosphate (PIP3), which in turn recruits and activates phosphatidylinositol-dependent 
kinase 1 (PDK1). Activated PDK1, in turn, phosphorylates and activates protein kinase B 
(PKB, also known as AKT). A subsequent signaling cascade downstream of AKT ultimately 
results in inhibition of cell cycle arrest and apoptosis, and increased cell proliferation and 
survival. The tumor-suppressor phosphatase and tensin homologue (PTEN) negatively 
regulates PI3K signalling by dephosphorylating PIP3, converting it back to PIP2 (Hawkins et 
al., 2006). 
The class IA PI3Ks are currently defined by their catalytic isoform, as the regulatory 
subunits appear to be functionally equivalent. Several studies have implicated class IA 
PI3Ks genes in glial tumors. Gain-of-function mutations in the PI3KCA gene have been 
found in some malignant gliomas (e.g., glioblastoma), with a reported mutation frequency 
up to 15% (Samuels et al., 2004; Gallia et al., 2006). Inactivation of PTEN by mutations or 
epigenetic mechanisms is a frequent event in high-grade gliomas (up to 50%), which results 
in uncontrolled PI3K signaling (Knobbe & Reifenberger, 2003; Ohgaki et al., 2004). Studies 
using elegant mouse models have recently shown that the specific inactivation of PTEN in 
the mouse brain caused its overgrowth and abnormal proliferation of astrocytes (Fraser et 
al., 2004). Also in mouse studies, inactivation of PTEN has been associated with increased 
angiogenesis, closely paralleling the progression from low-grade to high-grade 
astrocytomas in humans, which coincides with PTEN loss (Andrew Xiao et al., 2002; 2005).  
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Aberrant PI3K signaling commonly results in activation of Akt via phosphorylation of two 
key residues, T308 and S473, by PDK1 and the mammalian target of rapamycin (mTOR), 
respectively (Mora et al., 2004; Sarbassov et al., 2005). In fact, assessment of the 
phosphorylation status of these residues in Akt is often the method of choice for 
determining activation of the PI3K pathway in cell lines and primary tumors, including 
glioblastoma samples, 85% of which have been shown to exhibit activated Akt (Wang et al., 
2004). Additional mechanisms by which Akt activation may become dysregulated include 
decreased expression of PHLPP (PH domain leucine-rich repeat protein phosphatase, which 
dephosphorylates S473 in Akt), decreased expression of CTMP (C-terminal modulator 
protein, which binds to Akt and inhibits its phosphorylation), or overexpression of PIKE-A 
(phosphatidylinositol-3-kinase enhancer, which binds directly to phosphorylated Akt and 
enhances its anti-apoptotic function) in primary glioblastoma and glioma cell lines (Ahn et 
al., 2004). 
Despite most of the signaling pathways previously mentioned (p53, RB, RTK, MAPK, and 
PI3K/AKT pathways) are often considered as distinct entities, there is significant cross-talk 
and inter-dependence among them, which reinforces the inappropriate regulation of any 
single pathway perturbation. (Indeed, these pathways are sometimes referred to as genetic 
networks, to emphasize their highly complex relationships.) For example, since p53 
enhances transcription of PTEN (Stambolic et al., 2001), the loss of p53 in cells with 
constitutively active RTK signaling can further potentiate PI3K/AKT pathway activation. 
The NF1 tumor suppressor gene encodes neurofibromin-1, which functions primarily as a 
RAS negative regulator, and also plays a role in adenylyl cyclase and AKT-mTOR pathways. 
Loss of NF1 is a typical molecular aberration of WHO grade I pilocytic astrocytoma (Zhu & 
Parada, 2002), and is believed to be one of the precursor lesions in these tumors, as the 
absence of negative regulation of RAS oncoprotein may favor cell proliferation and, 
ultimately, tumor initiation. 
4.2.3 Cell cycle regulators 
Genes involved in cell cycle regulation have been frequently found mutated in glioma, 
highlighting the importance of such genes in cellular proliferation and senescence. The RB 
and p53 pathways, which regulate the cell cycle primarily by governing the G1-to-S-phase 
transition, are major targets of functional inactivation in glioma, through any of several 
molecular alterations. The inactivation of these key regulators renders tumors highly 
sensitive to uncontrolled cell proliferation driven by mitogenic signaling effectors, such as 
phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK). 
The RB protein exerts its anti-proliferative effects in quiescent cells by binding and 
sequestering the E2F family of transcription factors, preventing the transactivation of 
genes essential for cell cycle progression (Sherr & McCormick, 2002). Gliomas circumvent 
the RB-mediated negative regulation of the cell cycle by any of the following 
genetic/epigenetic aberrations: mutation of the Rb1 gene, loss of its chromosomal region 
(13q) when progression from low- to high-grade gliomas occurs, amplification of cyclin-
dependent kinases 4 and 6 (CDK4 and CDK6) genes (which encode negative regulators of 
RB activity), and inactivation of p16Ink4a (a negative regulator of CDKs) by allelic loss or 
DNA hypermethylation in high-grade gliomas (Louis et al., 2007). Even though the 
neutralization of the RB pathway alone is not sufficient to abrogate cell cycle control to 
the extent needed for cellular transformation (suggesting that other important cell cycle 
regulation pathways complement its activities in preventing gliomagenesis) (Xiao et al. 
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2002), the importance of its inhibition in progression from low- to higher-grade gliomas is 
underscored by the near-universal and mutually exclusive alterations of the molecular 
players of the RB pathway in both primary and secondary glioblastoma (Schmidt et al., 
1994; Ueki et al., 1996). 
The p53 tumor suppressor prevents the proliferation of cells with faulty genomes, mostly by 
halting the cell cycle in the G1 phase or by induction of an apoptotic program (Vousden & 
Lu, 2002). In sporadic (non-hereditary) gliomas, the p53 pathway is almost universally 
altered. A variety of molecular mechanisms may result in defective p53 function in glioma. 
Loss of p53 through either inactivating mutations in its DNA-binding domain or loss of 
chromosome 17p are common early events in the progression of secondary glioblastoma 
(Louis, 1994); in addition, germline p53 mutations in Li-Fraumeni patients, who have 
increased risk to develop gliomas, also underscore the importance of p53 in gliomagenesis 
(Malkin et al., 1990; Srivastava et al., 1990). Alternative inactivating alterations of the p53 
pathway in gliomas include deletion of p14ARF (whose protein stabilizes p53), amplification 
of the chromosomal region containing MDM2 and MDM4 genes (which encode negative 
regulators of p53 activity and expression) (Riemenschneider et al., 1999), and hemizygous 
deletion of the tumor suppressor gene CDH5 (whose protein plays a role in maintaining 
TP53 expression) (Bagchi et al., 2007). 
4.2.4 Isocitrate dehydrogenases (IDH1 and IDH2) genes 
Very recent studies have identified mutations in the genes encoding the cytosolic and 
mitochondrial isoforms of NADP+-dependent isocitrate dehydrogeneses (IDH1 and IDH2, 
respectively) in GBMs (Balss et al., 2008; Parsons et al., 2008; Ichimura et al., 2009; Watanabe 
et al., 2009; Yan et al., 2009; Zhao et al., 2009; Pollack et al., 2010; Christensen et al., 2011). 
These enzymes catalyze the decarboxylation of isocitrate to -ketoglutarate (-KG), in a 
reaction that utilizes NADP+ and produces NADPH. This cytosolic NAPDH is essential for 
the regeneration of reduced glutathione, which is important in the protection of cells against 
oxidative damage. These mutations in IDH1 and IDH2 are heterozygous and of somatic 
origin.  Until now, the mechanisms by which IDH mutant proteins contribute to 
gliomagenesis are not fully understood. The IDH1 R132H mutant variant, which is present 
in more than 90% of gliomas but rare in pilocytic astrocytomas, presents impaired substrate 
affinity, and dominantly inhibits wild-type IDH1 activity through the formation of 
catalytically inactive heterodimers (Zhao et al., 2009). The overexpression of mutant IDH1 
was shown to reduce the formation of -KG, and to increase the levels of HIF-1α, a critical 
transcription factor that promotes tumor growth under hypoxic conditions and whose 
stability depends on the levels of -KG. This HIF-1 regulation by mutant IDH1 suggested 
that this mutation may cause oncogenic gains of function. Indeed, a later study by Dang et 
al., (2009) showed that mutant IDH1 converts a -KG to 2-hydroxyglutarate (2-HG) in a 
NADPH-depend manner. Because mutations in IDH1 and IDH2 genes are restricted to a 
single amino acid, their detection for diagnostic purposes should be straightforward.  
Gliomas of astrocytic or oligodendrocytic lineage with IDH mutations have been shown to 
present distinct clinical and genetic characteristics as compared with gliomas with wild-type 
IDH genes (Yan et al., 2009), suggesting this mutation may be an early event in 
gliomagenesis from a stem/progenitor cell that can differentiate into both astrocytes and 
oligodendrocytes. Since IDH mutants occur in the large majority of WHO grade II or III 
gliomas, and in WHO grade IV secondary glioblastomas that develop from these lower-
www.intechopen.com
 
Molecular Hallmarks of Gliomas  
 
189 
grade precursor lesions, suggests that tumors with mutated IDH’s encompass a specific 
subgroup of glioblastomas. 
4.2.5 Molecular pathways to glioblastoma 
As previously mentioned, glioblastomas can be subdivided into primary or secondary 
GBMs, based on their clinical and biological differences. Primary GBMs are by far the 
most common, affect older patients, and are genetically characterized by EGFR 
amplification and mutations, LOH of chromosome 10q, and deletion of the PTEN and the 
p16INK4a genes (Louis et al., 2007). Secondary GBMs affect younger patients who had 
previously been affected by a lower grade astrocytoma, and are molecularly characterized 
by mutations in the TP53 gene, overexpression of PDGFR, abnormalities in the p16 and Rb 
pathways, and LOH of chromosome 10q  (Louis et al., 2007). Importantly, some of these 
molecular abnormalities are not exclusive for a specific glioblastoma subtype, but are 
rather present at significantly different frequencies (for example, the frequency of TP53 
mutation in secondary GBM is more than ~65%, but only ~28% in primary GBM) (Ohgaki 
& Kleihues, 2007). Despite being morphologically and clinically indistinguishable, as 
reflected by an equally poor prognosis when adjusted for patient age, primary and 
secondary GBMs have markedly distinct molecular features, at the levels of gene 
transcriptional patterns and DNA copy number aberrations (Furnari et al., 2007). Thus, 
these molecular distinctions strongly suggest that these GBM entities may respond 
differently to targeted molecular therapies, warranting the need to change the current 
standardize clinical management of these truly distinct diseases. 
4.2.6 Epigenetic changes in glioma 
In addition to genetic aberrations, gliomas also present a variety of epigenetic alterations, 
defined as mitotically heritable changes in gene expression that are not due to changes in the 
primary DNA sequence. The most well-studied epigenetic changes in gliomas occur 
primarily at two levels: DNA methylation at CpG dinucleotides, and post-translational 
modifications of histone tails. Nevertheless, other epigenetic mechanisms include noncoding 
RNAs (e.g., microRNAs and small nucleolar RNAs), accumulation of histone variants, and 
chromatin remodeling, and may also be altered in brain tumors. Typical changes in DNA 
methylation levels observed in gliomas, as in other human tumors, include CpG island 
hypermethylation (associated with tumor suppressor gene silencing), gene-specific 
hypomethylation (resulting in aberrant oncogene activation), and genome-wide 
hypomethylation (potentially leading to chromosomal instability, loss of imprinting, and 
uncontrolled cellular proliferation). The histone modifications are quite more complex: 
firstly, because of the great variety of modifications that can occur in different histones 
(including, methylation, acetylation, phosphorylation, ubiquitylation, sumoylation, among 
others), and secondly, because a single histone tail residue can be mono-, di-, or tri-
methylated on a single, specific lysine. In general, epigenetics is just another layer of gene 
expression regulation that, when altered in specific genes, may favor tumor formation and 
progression. While genetic and epigenetic changes in gliomas have been mostly studied 
independently, there is evidence that these mechanisms interact on specific genes, signaling 
pathways, and chromosomal domains. A summary of some of the epigenetic changes 
previously found in gliomas is presented in Table 1, and elegantly reviewed by Nagarajan & 
Costello, 2009. 
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Glioma type 
Subtype 
(WHO grade) 
Genetic Alterations 
Epigenetic 
Alterations 
Astrocytic tumors 
Pilocytic 
astrocytoma (I) 
NF1 loss 
CpG island 
hypermethylation in 
tumor suppressor 
genes (MGMT, 
PCDH-gamma-A11, 
EMP3, THBS1, 
RASSF1A, CRBP1, 
TMS1, p16, SLC5A8, 
RB, PTEN, TP53, 
p14ARF, TIMP3) 
Genome-wide ( 
“global”) DNA 
hypomethylation 
Aberrant levels of 
histone post-
translational 
modifications (e.g., 
acetylation, 
methylation) 
 
Diffuse 
astrocytoma (II) 
LOH 17p; TP53 
mutations; PDGFRA 
amplification 
Anaplastic 
astrocytoma (III) 
Gains of chromosome 
7; Mutations in TP53, 
RB1, CDK4, CDKN2A; 
Deletions of 6p, 9p, 
11p, 22q 
Gliobastoma (IV) 
Amplification of 
EGFR, p14ARF, CDK4, 
MDM2, MDM4; 
Homozygous deletion 
of CDKN2A, RB1; 
Mutation of TP53, 
RB1, PTEN, IDH1, 
IDH2; 
Allelic loss of 19q, 13q 
Oligodendroglial 
tumors 
Oligodendroglioma
(II) 
LOH 1p/19q; 
TP53 mutations 
Anaplastic 
oligodendroglioma 
(III) 
LOH 1p/19q; 10q 
deletion; CDKN2A 
Amplification EFGR 
Mutation of IDH1 
Oligoastrocytic 
tumors 
Oligoastrocytoma 
(II) 
LOH 1p/19q; TP53 
mutations 
Anaplastic 
oligoastrocytoma 
(III) 
LOH 1p/10q; 
Mutations of IDH1, 
TP53 
Table 1. Common genetic and epigenetic hallmarks of gliomas 
5. Molecular prognostic factors of malignant glioma 
Recent studies started to identify potential biological and molecular characteristics in the 
tumors that may have prognostic value and help in making therapeutic decisions (Phillips et 
al., 2006), although such studies clearly require validation in prospectively followed and 
uniformly treated patients. Until now, work on the identification of prognostic markers in 
gliomas grants reasons for both optimism and caution with respect to improvements in the 
diagnosis and treatment of patients. In practice, the multitude of studies on the 
identification of such markers has led so far to development of only one molecular test with 
clinical relevance: 1p/19q testing in oligodendrogliomas. Much more effort is required for 
the identification of markers that truly and consistently distinguish glioma patients in ways 
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that can assist therapeutic decisions. Below we briefly discuss the current most promising 
molecular prognostic factors in these tumors, which are summarized in Table 2. 
 
Molecular Prognostic Marker Glioma Type 
Chromosome 1p/19q co-deletion Oligodendroglioma and oligoastrocytoma 
MGMT promoter methylation GBM and anaplastic astrocytoma 
Loss of chromosome 10 GBM 
Activation of the PI3K/AKT pathway  GBM 
Activation of MAPK members GBM 
EGFR mutation (EGFRvIII) GBM 
PTEN expression (wild-type) GBM 
Molecular signatures (proneural, 
proliferative and mesenchymal) 
GBM 
High expression of angiogenic genes 
Diffusely infiltrating gliomas of all 
histologic types 
Stem-cell like gene expression signatures GBM 
CHI3L1 (YKL-40) expression GBM 
PTEN and DLL3 expression GBM 
EGFR expression GBM 
HOXA overexpression GBM 
IDH1-2 mutations 
All gliomas, but not very frequent in 
primary GBM 
Table 2. Selected Molecular Prognostic Markers for Gliomas. 
5.1 Malignant astrocytomas 
O6-methylguanine-DNA methyltransferase (MGMT, also known as AGT) is an important 
DNA repair enzyme that contributes to glioblastoma resistance to temozolomide. The 
methyl group at the O6 position of guanine can be removed by MGMT, which is consumed 
by this event (Spiro et al., 2001). In a similar study to the one from the EORTC–NCIC, Hegi 
et al., 2005, examined the DNA methylation at the promoter region of the MGMT gene in 
tumor samples from glioblastoma patients. This epigenetic event silences MGMT, which 
decreases tumor cells’ ability to repair temozolomide-induced DNA damage, resulting in 
increased susceptibility of the tumor cells to temozolomide. Hegi reported that glioblastoma 
patients with a methylated MGMT promoter who were treated with temozolomide had a 
significantly longer median overall survival (21.7 months) and a higher 2-year survival rate 
(46%) than patients without MGMT promoter methylation who were similarly treated with 
temozolomide (median survival of only 12.7 months and a 2-year survival rate of 13.8%), 
suggesting that glioblastoma patients whose tumors do not have a methylated MGMT 
promoter do not benefit from temozolomide. Despite the striking and encouraging findings 
supporting MGMT as a glioma prognostic marker and a specific predictor of temozolomide-
based chemotherapy, there is a significant body of controversial data surrounding the 
reproducibility of such findings (summarized in Costa et al., 2010a). Much of the 
controversy around the prognostic value of MGMT is due in part to studies including very 
heterogeneous groups of patients, with different glioma histologies, grades, and treatment 
types often grouped together in the same analysis. Additionaly, different studies analyzed 
www.intechopen.com
 
Molecular Targets of CNS Tumors 
 
192 
MGMT at different levels, including methylation by methylation-specific PCR, mRNA 
expression by RT-PCR, and protein levels by immunohistochemistry and quantitative 
immunofluorescence. Due to the widely acknowledged need of replicating Hegi’s findings, 
we investigated the potential of MGMT methylation as a prognostic marker of glioblastoma 
in a set of 90 prospectively followed patients uniformly treated with postoperative 
temozolomide-based chemoradiation. In line with some other reports, we found a trend for 
longer overall and progression-free survival in glioblastoma patients whose tumors had 
MGMT promoter methylation, but the differences failed to reach statistical significance in 
our data set (Costa et al., 2010a). 
Recent evidences are revealing striking similarities between developmental and tumorigenic 
processes, suggesting that some of the molecular regulatory mechanisms necessary for 
normal development may be equally relevant in tumors. Homeobox (HB) genes encode 
transcription factors that play critical roles during normal development. These genes are 
broadly divided into two classes: class I includes clustered homeobox (HOX) genes, while 
class II includes divergent HB (non-HOX) genes that are dispersed throughout the genome 
(McGinnis & Krumlauf, 1992). The expression of some HOX genes has been shown to be 
altered in leukemias and several types of solid tumors. In recent years, a growing body of 
data has been implicating the aberrant expression of HOXA genes as an important 
mechanism in the pathophysiology of malignant astrocytomas. A study by (Abdel-Fattah et 
al., 2006) assessed the expression status of all HOX genes in primary astrocytomas and non-
tumoral brain specimens, showing that a portion of these genes are aberrantly 
overexpressed in malignant astrocytomas. However, the relevance of these genes in glioma 
pathogenesis, malignancy, and prognosis was not addressed in that study. Later, Murat et 
al., 2008, suggested HOX genes may be part of a glioma stem cell signature with prognostic 
significance in patients treated with chemo-radiotherapy. We have recently shown that 
several HOXA genes are preferentially overexpressed in high-grade rather than in low-
grade primary astrocytomas, and we have implicated the reactivation of HOXA9 expression 
in GBM as a novel, independent, and negative prognostic factor in 2 independent sets of 
GBM patients (Costa et al., 2010b). Additionally, HOXA9 reactivation was particularly 
frequent in a subgroup of GBM with aberrant chromosomal domains of transcriptional 
activation encompassing the HOXA cluster. Importantly, we demonstrated the PI3K-
associated epigenetic mechanism by which this domain of activation is reversible: activation 
of the PI3K pathway in GBM cells decreased the levels of histone H3 lysine 27 
trimethylation through inhibition of EZH2, a key histone methyltransferase. Finally, we 
provided functional data on the effects of HOXA9 expression in GBM cells and 
immortalized astrocytes, which support its pro-proliferative and anti-apoptotic properties. 
Our findings revealed prognostic and therapeutic implications for oncogenic expression of 
the developmental transcription factor HOXA9 in malignant brain tumors, including the 
evaluation of PI3K inhibitors, which are being extensively tested in clinical trials. Finally, a 
recent study by (Gaspar et al., 2010) showed that high levels of HOX genes expression was a 
signature of resistance to temozolomide in pediatric GBM cell lines; in addition, pediatric 
high-grade glioma patients whose tumors expressed HOXA genes (particularly HOXA9 and 
HOXA10) presented significantly shorter survival. Taken together, these recent studies point 
out to a very relevant role of HOXA genes in rendering high-grade gliomas even more 
malignant and resistant to therapy, resulting in particularly lethal tumors. 
A genomic study by Parson and colleagues in 2008 showed that a subset of GBM patients 
had IDH1 R132H mutations, and that this mutation occurred mostly in younger patients 
(mean age 33 years in IDH1 mutant patients versus 53 years for patients with wild-type 
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IDH1). In addition, this mutation was particularly frequent in secondary GBMs (5 out of 6 
secondary GBMs versus 7 out of 99 primary GBMs with IDH1 mutation), and was 
significantly associated with an increase in patients overall survival (Parsons et al., 2008). 
Yan et al. (2009) subsequently showed that IDH1 mutation was commonly present in a 
variety of gliomas, including diffuse astrocytoma, anaplastic astrocytoma, and 
oligodendroglioma. In addition, the authors also identified a mutation affecting the 
analogous aminoacid residue (R172) of the IDH2 gene, which was present in tumors without 
IDH1 mutation. Importantly, the presence of either IDH mutation was associated with better 
survival of GBM and anaplastic astrocytoma patients. Christensen et al. (2011) also verified 
that IDH1 mutation occurs more frequently than IDH2 mutation in gliomas, and showed 
that the presence of IDH1 or IHD2 mutation was significantly associated with better survival 
of glioma patients, independently of patient age, sex, and grade-specific histology. 
5.2 Malignant oligodendrogliomas and oligoastrocytomas 
Tumors with 1p/19q codeletion are particularly sensitive to chemotherapy with PCV, with 
response rates as high as 100%, whereas patients whose tumors do not present 1p/19q 
codeletion show response rates of 23-31% (Ino et al., 2001; Cairncross et al., 1998). Indeed, 
oligodendroglioma is the first CNS neoplasm in which a molecular signature (1p and 19q 
codeletion) has been categorically associated with patient outcome within the context of 
large clinical trials (Felsberg et al., 2004). Even though the reasons for such associations are 
still unclear, the status of 1p and 19q, rather than classic histological analysis, is currently 
used as an eligibility criterion in studies involving patients with pure or mixed anaplastic 
oligodendrogliomas. This truly reflects a paradigm shift in the design of clinical trials for 
patients with these tumors, and has been regarded as a key example of the value of 
molecular signatures as prognostic markers of disease. Again, codeletion of 1p/19q was 
associated with improved survival in both studies. Although most studies of patients with 
pure or mixed oligodendroglioma were performed with PCV chemotherapy, temozolomide 
is arguably likely to have similar activity with less side effects (van den Bent, 2007; Yung et 
al., 1999); however, studies comparing the efficacy of these two chemotherapeutic regimens 
are still lacking. 
6. Conclusion 
Human gliomas are particularly dramatic diseases, not only because of their high lethality, 
but also because their etiological and prognostic factors are still not fully understood. 
Integrating multi-disciplinary teams to collaborate in the identification of new molecular 
and exogenous glioma risk factors is urgent. Possibly even more important is to rapidly 
improve the clinical management of glioma patients. While the current therapies used for 
malignant glioma and patients’ outcome are not satisfactory, the recent insights on the 
biological and clinical features of glioma offer appealing opportunities for the development 
of more effective targeted therapy. The use of comprehensive genome-wide approaches to 
analyze genetic and epigenetic alterations, as it is the case of The Cancer Genome Atlas 
(TCGA, http://cancergenome.nih.gov/about/mission.asp), may foster our understanding 
of the complex mechanisms underlying the various layers of glioma biology (formation, 
progression, resistance to therapy, etc) and aid in the identification of new avenues for drug 
development, particularly targeted therapies. Indeed, recent developments in second 
generation sequencing technologies and its more widespread application hold promise to 
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achieve these goals. Much more effort is required for the identification of molecular markers 
that truly and consistently distinguish glioma patients in ways that can assist therapeutic 
decisions. The integration of clinical and molecular data, now becoming available using 
recently developed tools such as  gene microarrays, proteomics, and molecular imaging, will 
take us to an era where more targeted and effective treatments may be developed and 
implemented. We are cautiously optimistic that the development of a consensual molecular 
marker set predictive of therapy response in malignant gliomas, particularly glioblastoma, 
can arise in the future. Such marker set would substantially change the clinical management 
of these patients as it could aid the neuro-oncologist in individualizing therapy for each 
patient. Particularly, such marker set could allow the identification of the subset of patients 
who are likely to benefit from a specific therapy alone. Conversely, the ability to 
prospectively identify patients who are not be likely to respond to such therapy would also 
allow those patients to make an informed decision to participate in clinical trials with 
alternative novel therapies, avoiding adverse effects of specific treatments in the absence of 
anticipated clinical benefit. Additionally, a more in depth knowledge of the molecular 
determinants of treatment resistance could be the rational for designing the next generation 
of clinical trials for these highly malignant tumors. Finally, the identification of true 
molecular markers is also invaluable in the first steps of new drugs’ development. Despite 
all the gaps in our understanding, a large amount of information is now available about the 
clinical and biological behavior of gliomas, and the molecular pathways that are relevant in 
their genesis and progression. In the quest toward individualization of glioblastoma 
treatment, the discovery of particular tumor molecular features, such as the status of MGMT 
methylation, IDH1-2 mutations, and HOXA genes expression, may be the initial building 
blocks of a panel of molecular markers that truly have clinical implications. The challenge in 
the future will not only be to discover additional molecular markers of glioblastoma, but 
also to integrate all this new knowledge in an interdisciplinary manner to create an 
intelligible puzzle, which allows a more rational and efficient fight against this disease. 
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